

## Recommended antibiotics for chemoprophylaxis or treatment

Table 1. Recommended antibiotics for chemoprophylaxis or treatment

	Clarithromycin*	Azithromycin*	Erythromycin	Co-trimoxazole*,a
Neonates (less than one month)	Preferred in neonates 7.5mg/kg twice a day for 7 days	10mg/kg once a day for 3 days	Not recommended due to association with hypertrophic pyloric stenosis	Not licensed for infants below 6 weeks
Infants (one month to 12 months)	One month to 11 years: Under 8kgs 7.5mg/kg twice a day for 7 days 8 to 11kg	One to 6 months: 10mg/kg once a day for 3 days Older than 6 months:	One to 23 months: 125mg every 6 hours for 7 days≠	6 weeks to 5 months: 120mg twice a day for 7 days
and	62.5mg twice a day for 7 days  12 to 19kg	10mg/kg (max 500mg) once a day for 3 days	2 to 7 years: 250mg every 6 hours for 7 days≠	6 months to 5 years: 240mg twice a day for 7 days
Children (older than 12 months)	125mg twice a day for 7 days 20 to 29kg 187.5mg twice a day for 7 days 30 to 40kg 250mg twice a day for 7 days 12 to 17 years: 500mg twice a day for 7 days		8 to 17 years: 500mg every 6 hours for 7 days≠	6 to 11 years: 480mg twice a day for 7 days  12 to 17 years: 960mg twice a day for 7 days
Adults	500mg twice a day for 7 days	500mg once a day for 3 days	500mg every 6 hours for 7 days≠	960mg twice a day for 7 days
Pregnant women <sup>b</sup>	Not recommended	Not recommended	Preferred antibiotic – not known to be harmful	Contraindicated in pregnancy

<sup>≠</sup> Doses can be doubled in severe infections, note that administering antibiotics 6 hourly may be troublesome for children in full-time education.

The above information has been taken from BNF 75 (March 2018) and BNF for Children 2017 to 2018. The recommendation to use azithromycin for infants less than 6 months of age is based on advice from experts on the Pertussis Guidelines Group and Centers for Disease Control and Prevention (CDC) guidelines. Azithromycin and co-trimoxazole doses are extrapolated from treatment of respiratory tract infections (see <u>Guidelines for the public health management of pertussis in England May 2018</u>).

<sup>\*</sup> Please note that the doses for treatment and prophylaxis are the same.

<sup>&</sup>lt;sup>a</sup> Consider if macrolides contra-indicated or not tolerated.

b For pregnant contacts, a risk assessment would need to be done to looks at the risk and benefits of antibiotic therapy or prophylaxis. The aim of treating or prophylaxing women in pregnancy is to prevent transmission to the newborn infant and should be considered in those who have not received a pertussis containing vaccine more than one week and less than 5 years prior. Where possible, pregnant women should begin treatment at least 3 days prior to delivery.

## About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

<u>UKHSA</u> is an executive agency, sponsored by the <u>Department of Health and Social Care</u>.

## © Crown copyright 2023

For queries relating to this document, please contact: <a href="mailto:immunisation@ukhsa.gov.uk">immunisation@ukhsa.gov.uk</a>

Published: June 2023

Publishing reference: GOV-14717

## **OGL**

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit <u>OGL</u>. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the Sustainable Development Goals

